Last reviewed · How we verify
Ticlopidine and itraconazole
This is a combination of ticlopidine (a platelet aggregation inhibitor) and itraconazole (an antifungal agent), used together to manage thrombotic and fungal complications.
This is a combination of ticlopidine (a platelet aggregation inhibitor) and itraconazole (an antifungal agent), used together to manage thrombotic and fungal complications. Used for Thrombotic prevention (ticlopidine component), Fungal infection treatment (itraconazole component).
At a glance
| Generic name | Ticlopidine and itraconazole |
|---|---|
| Sponsor | Turku University Hospital |
| Drug class | Antiplatelet agent + Antifungal agent |
| Target | ADP receptor (P2Y12) for ticlopidine; Fungal CYP51 for itraconazole |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular / Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Ticlopidine inhibits platelet aggregation by blocking ADP-induced platelet activation, reducing thrombotic events. Itraconazole is a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol demethylase, preventing ergosterol synthesis. The combination addresses both antiplatelet and antifungal therapeutic needs, though this pairing is unusual and likely reflects a specific clinical scenario rather than a synergistic mechanism.
Approved indications
- Thrombotic prevention (ticlopidine component)
- Fungal infection treatment (itraconazole component)
Common side effects
- Neutropenia (ticlopidine)
- Thrombotic thrombocytopenic purpura (ticlopidine)
- Nausea (itraconazole)
- Hepatotoxicity (itraconazole)
- Drug-drug interactions
Key clinical trials
- Effect of Itraconazole and Ticlopidine on the Pharmacokinetics and Pharmacodynamics of Oral Tramadol (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ticlopidine and itraconazole CI brief — competitive landscape report
- Ticlopidine and itraconazole updates RSS · CI watch RSS
- Turku University Hospital portfolio CI